TENON MEDICAL INC (TNON)
US88066N2045 - Common Stock
TNON gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 188 industry peers in the Health Care Equipment & Supplies industry. The financial health of TNON is average, but there are quite some concerns on its profitability. TNON shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
In the past year TNON has reported negative net income.
In the past year TNON has reported a negative cash flow from operations.
In the past 5 years TNON always reported negative net income.
In the past 5 years TNON always reported negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -230.90%, TNON is not doing good in the industry: 92.51% of the companies in the same industry are doing better.
TNON has a worse Return On Equity (-1666.83%) than 91.44% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -230.9% | ||
| ROE | -1666.83% | ||
| ROIC | N/A |
ROA(3y)-164.07%
ROA(5y)-166.48%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TNON has a Gross Margin (60.32%) which is in line with its industry peers.
In the last couple of years the Gross Margin of TNON has declined.
TNON does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 60.32% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-17.32%
GM growth 5YN/A
2. Health
2.1 Basic Checks
TNON does not have a ROIC to compare to the WACC, probably because it is not profitable.
TNON has less shares outstanding than it did 1 year ago.
The debt/assets ratio for TNON is higher compared to a year ago.
2.2 Solvency
TNON has an Altman-Z score of -20.54. This is a bad value and indicates that TNON is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -20.54, TNON is doing worse than 87.17% of the companies in the same industry.
There is no outstanding debt for TNON. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -20.54 |
ROIC/WACCN/A
WACC8.79%
2.3 Liquidity
A Current Ratio of 1.20 indicates that TNON should not have too much problems paying its short term obligations.
TNON's Current ratio of 1.20 is on the low side compared to the rest of the industry. TNON is outperformed by 87.70% of its industry peers.
TNON has a Quick Ratio of 1.02. This is a normal value and indicates that TNON is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of TNON (1.02) is worse than 79.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.2 | ||
| Quick Ratio | 1.02 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 78.81% over the past year.
TNON shows a strong growth in Revenue. In the last year, the Revenue has grown by 324.35%.
The Revenue has been growing by 318.31% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)78.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68.92%
Revenue 1Y (TTM)324.35%
Revenue growth 3Y318.32%
Revenue growth 5YN/A
Sales Q2Q%-5.72%
3.2 Future
The Earnings Per Share is expected to grow by 37.12% on average over the next years. This is a very strong growth
Based on estimates for the next years, TNON will show a very strong growth in Revenue. The Revenue will grow by 60.82% on average per year.
EPS Next Y74.68%
EPS Next 2Y37.12%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year36.92%
Revenue Next 2Y60.82%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for TNON. In the last year negative earnings were reported.
Also next year TNON is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
TNON's earnings are expected to grow with 37.12% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.12%
EPS Next 3YN/A
5. Dividend
5.1 Amount
TNON does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TENON MEDICAL INC
NASDAQ:TNON (11/22/2024, 5:59:02 PM)
After market: 2.54 0 (0%)2.54
-0.09 (-3.42%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap7.98M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -230.9% | ||
| ROE | -1666.83% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 60.32% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.56
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.2 | ||
| Quick Ratio | 1.02 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)78.81%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y74.68%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)324.35%
Revenue growth 3Y318.32%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y